Superior Planning, LLC’s Aquestive Therapeutics AQST Stock Holding History

Superior Planning, LLC’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$195	Buy	+42	New	+$187	﹤0.01%	2032

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Superior Planning, LLC's AQST Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Aquestive Therapeutics (AQST) in Q3 2026: 42 shares worth $195. The stake represents ﹤0.01% of the portfolio and ranks #2032 among its holdings.

104 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

Superior Planning, LLC held 42 shares of Aquestive Therapeutics worth $195 as of Q3 2026.
Aquestive Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Aquestive Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #2032 holding.
104 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.